The U.S. Food and Drug Administration approves Pimjetmi (pimicotinib), a small-molecule treatment for certain adults with symptomatic tenosynovial giant cell tumor (TGCT). The approval covers specific patient populations, including those who are at high risk for surgery, and the therapy is described as systemic and oral.
Context on the drug’s development and licensing varies by outlet. One report highlights that pimicotinib was developed by Abbisko Therapeutics and licensed by Merck KGaA, framing the approval as a new treatment option in the U.S. and citing durable tumor response and clinically meaningful improvements in clinical outcome assessments. Another outlet emphasizes the regulatory milestone for this rare benign soft-tissue tumor and characterizes pimicotinib as an oral, selective inhibitor linked to colony-stimulating factor biology, focusing on patient selection based on surgical risk.